The efficacy of etidronate, a bisphosphonate, was assessed as a treatment for the inner ear symptoms of otosclerosis in a retrospective case review of 896 patients diagnosed with otosclerosis, with primary complaints of dizziness, hearing loss, tinnitus or Meniere's syndrome. The diagnosis of otosclerosis was based on smallpixel computed tomography of the temporal bones. Of the 896 patients pla...

The effect of in vivo administration of disodium ethan-l-hydroxy-1.1-diphosphonate (EHDP) on the mitogenic response of thymocytes or spleen cells were studied in young rats. When rats (2-3 weeks of age) were injected with EHDP (10mg/kg/day) subcutaneously for more than 6 days or injected once with EHDP (100mg/kg) subcutaneously or intraperitoneally, lipopolysaccharide-induced proliferative resp...

Osteoporosis is a well known consequence of glucocorti-coid treatment that can result in significant morbidity and mortality. Glucocorticoid-induced bone loss occurs early, usually within 6–12 months of starting therapy. During this time the rate of bone loss is rapid before decreasing or reaching a plateau. 1 2 4 Clinically this decrease in bone mineral density puts patients at an increased ri...

Luminal and contraluminal stop-flow microperfusion was applied, and the apparent Ki values (mmol/l) against the luminal phosphate and the contraluminal p-aminohippurate (PAH), sulfate and dicarboxylate transport systems were evaluated. Luminal phosphate transporter: Among the 20 compounds tested only phosphonoformate (foscarnet), etidronate, and clodronate have a good affinity (app.Ki < 1 mmol/...

We have shown that in patients with COPD, myocardial efficiency during exercise is enhanced following acute elevations of plasma phosphate (Pi). A decrease in Hb-O2 affinity (increase in P50) was not responsible for the improvement. We postulated that the physiologic benefit was due to the acute reversal of a subclinical myocardial Pi depletion. To further test this hypothesis in a chronic stat...